What is United Therapeutics Corp.'s earnings per share (EPS)?

United Therapeutics Corp. (UTHR) reported diluted earnings per share of $27.86 for fiscal year 2025. This represents a 13.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

United Therapeutics Corp. Financials

UTHR

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows United Therapeutics Corp. (UTHR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 84/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

100

United Therapeutics Corp. has an operating margin of 46.9%, meaning the company retains $47 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 47.9% the prior year.

Growth

United Therapeutics Corp.'s revenue grew 10.6% year-over-year to $3.2B, a solid pace of expansion. This earns a growth score of 51/100.

Leverage

100

United Therapeutics Corp. carries a low D/E ratio of 0.11, meaning only $0.11 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.60, United Therapeutics Corp. holds $6.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

100

United Therapeutics Corp. converts 32.7% of revenue into free cash flow ($1.0B). This strong cash generation earns a score of 100/100.

Returns

United Therapeutics Corp.'s ROE of 18.8% shows moderate profitability relative to equity, earning a score of 53/100. This is up from 18.6% the prior year.

Altman Z-Score Safe

22.16

United Therapeutics Corp. scores 22.16, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($25.0B) relative to total liabilities ($783.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

United Therapeutics Corp. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.17x

For every $1 of reported earnings, United Therapeutics Corp. generates $1.17 in operating cash flow ($1.6B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

76.5x

United Therapeutics Corp. earns $76.5 in operating income for every $1 of interest expense ($1.5B vs $19.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.2B

YoY+10.6%

5Y CAGR+16.5%

10Y CAGR+8.1%

United Therapeutics Corp. generated $3.2B in revenue in fiscal year 2025. This represents an increase of 10.6% from the prior year.

EBITDA

$1.6B

YoY+8.9%

5Y CAGR+19.7%

10Y CAGR+8.0%

United Therapeutics Corp.'s EBITDA was $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.9% from the prior year.

Net Income

$1.3B

YoY+11.7%

5Y CAGR+21.0%

10Y CAGR+7.4%

United Therapeutics Corp. reported $1.3B in net income in fiscal year 2025. This represents an increase of 11.7% from the prior year.

EPS (Diluted)

$27.86

YoY+13.1%

5Y CAGR+19.3%

10Y CAGR+8.2%

United Therapeutics Corp. earned $27.86 per diluted share (EPS) in fiscal year 2025. This represents an increase of 13.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.0B

YoY-3.7%

5Y CAGR+8.4%

10Y CAGR+12.1%

United Therapeutics Corp. generated $1.0B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 3.7% from the prior year.

Cash & Debt

$1.6B

YoY-8.3%

5Y CAGR+16.1%

10Y CAGR+6.5%

United Therapeutics Corp. held $1.6B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

44M

YoY-2.7%

5Y CAGR-0.4%

10Y CAGR-0.4%

United Therapeutics Corp. had 44M shares outstanding in fiscal year 2025. This represents a decrease of 2.7% from the prior year.

Margins & Returns

Gross Margin

87.9%

YoY-1.3pp

5Y CAGR-4.8pp

10Y CAGR-7.4pp

United Therapeutics Corp.'s gross margin was 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the prior year.

Operating Margin

46.9%

YoY-1.0pp

5Y CAGR+6.9pp

10Y CAGR-0.8pp

United Therapeutics Corp.'s operating margin was 46.9% in fiscal year 2025, reflecting core business profitability. This is down 1.0 percentage points from the prior year.

Net Margin

41.9%

YoY+0.4pp

5Y CAGR+7.2pp

10Y CAGR-2.5pp

United Therapeutics Corp.'s net profit margin was 41.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.4 percentage points from the prior year.

Return on Equity

18.8%

YoY+0.3pp

5Y CAGR+3.6pp

10Y CAGR-22.2pp

United Therapeutics Corp.'s ROE was 18.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$550.0M

YoY+14.3%

5Y CAGR+9.0%

10Y CAGR+8.4%

United Therapeutics Corp. invested $550.0M in research and development in fiscal year 2025. This represents an increase of 14.3% from the prior year.

Share Buybacks

$1.0B

YoY+0.0%

10Y CAGR+9.7%

United Therapeutics Corp. spent $1.0B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 0.0% from the prior year.

Capital Expenditures

$520.5M

YoY+111.2%

5Y CAGR+54.4%

10Y CAGR+26.5%

United Therapeutics Corp. invested $520.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 111.2% from the prior year.

UTHR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.2B+10.6%	$2.9B+23.6%	$2.3B+20.2%	$1.9B+14.9%	$1.7B+13.6%	$1.5B
Cost of Revenue	$384.4M+24.1%	$309.7M+20.3%	$257.5M+69.9%	$151.6M+23.8%	$122.5M+13.3%	$108.1M
Gross Profit	$2.8B+9.0%	$2.6B+24.0%	$2.1B+16.0%	$1.8B+14.2%	$1.6B+13.7%	$1.4B
R&D Expenses	$550.0M+14.3%	$481.0M+17.9%	$408.0M+26.4%	$322.9M-40.2%	$540.1M+51.0%	$357.7M
SG&A Expenses	$755.8M+6.5%	$709.7M+48.8%	$477.1M-1.0%	$482.1M+3.2%	$467.0M	N/A
Operating Income	$1.5B+8.4%	$1.4B+16.2%	$1.2B+20.9%	$979.7M+76.2%	$555.9M-6.4%	$593.6M
Interest Expense	$19.5M-54.5%	$42.9M-27.7%	$59.3M+83.0%	$32.4M+74.2%	$18.6M-20.9%	$23.5M
Income Tax	$379.2M+10.3%	$343.9M+18.8%	$289.5M+29.6%	$223.3M+89.1%	$118.1M-4.8%	$124.1M
Net Income	$1.3B+11.7%	$1.2B+21.4%	$984.8M+35.4%	$727.3M+52.9%	$475.8M-7.6%	$514.8M
EPS (Diluted)	$27.86+13.1%	$24.64+24.4%	$19.81+32.1%	$15.00+49.1%	$10.06-12.8%	$11.54

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$790.2M-1.2%	$799.5M+0.1%	$798.6M+0.5%	$794.4M+7.9%	$735.9M-1.7%	$748.9M+4.8%	$714.9M+5.5%	$677.7M
Cost of Revenue	$103.4M+2.5%	$100.9M+15.2%	$87.6M-5.3%	$92.5M+21.9%	$75.9M-8.7%	$83.1M+6.8%	$77.8M+6.7%	$72.9M
Gross Profit	$686.8M-1.7%	$698.6M-1.7%	$711.0M+1.3%	$701.9M+6.3%	$660.0M-0.9%	$665.8M+4.5%	$637.1M+5.3%	$604.8M
R&D Expenses	$139.5M+9.4%	$127.5M-4.9%	$134.0M-10.1%	$149.0M+11.4%	$133.8M+29.3%	$103.5M-25.9%	$139.6M+34.1%	$104.1M
SG&A Expenses	$190.6M+4.4%	$182.6M-14.1%	$212.5M+24.9%	$170.1M+0.9%	$168.5M-23.1%	$219.2M+23.4%	$177.6M+23.0%	$144.4M
Operating Income	$356.7M-8.2%	$388.5M+6.6%	$364.5M-4.8%	$382.8M+7.0%	$357.7M+4.3%	$343.1M+7.3%	$319.9M-10.2%	$356.3M
Interest Expense	$3.1M+3.3%	$3.0M-58.9%	$7.3M+19.7%	$6.1M-22.8%	$7.9M-21.8%	$10.1M-12.9%	$11.6M-12.8%	$13.3M
Income Tax	$79.7M-19.7%	$99.3M+0.4%	$98.9M-2.4%	$101.3M+6.4%	$95.2M+19.7%	$79.5M+3.0%	$77.2M-16.1%	$92.0M
Net Income	$364.3M+7.6%	$338.7M+9.4%	$309.5M-3.9%	$322.2M+6.9%	$301.3M-2.5%	$309.1M+11.1%	$278.1M-9.3%	$306.6M
EPS (Diluted)	N/A	$7.16+11.7%	$6.41-3.3%	$6.63	N/A	$6.39+9.2%	$5.85-5.2%	$6.17

UTHR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.9B+7.0%	$7.4B+2.7%	$7.2B+18.6%	$6.0B+16.9%	$5.2B+12.0%	$4.6B
Current Assets	$3.7B-4.4%	$3.9B+9.1%	$3.6B+5.0%	$3.4B+45.5%	$2.3B+7.2%	$2.2B
Cash & Equivalents	$1.6B-8.3%	$1.7B+40.5%	$1.2B+25.6%	$961.2M+7.4%	$894.8M+21.1%	$738.7M
Inventory	$183.1M+16.0%	$157.9M+41.2%	$111.8M+9.6%	$102.0M+8.7%	$93.8M+8.4%	$86.5M
Accounts Receivable	$350.2M+25.4%	$279.3M+0.1%	$278.9M+26.5%	$220.4M+10.9%	$198.7M+26.2%	$157.4M
Goodwill	$32.3M0.0%	$32.3M-4.2%	$33.7M+20.4%	$28.0M0.0%	$28.0M0.0%	$28.0M
Total Liabilities	$783.8M-14.8%	$920.0M-22.2%	$1.2B-5.3%	$1.2B+3.1%	$1.2B-0.8%	$1.2B
Current Liabilities	$560.6M-24.0%	$738.1M-8.2%	$804.4M+134.4%	$343.2M+12.4%	$305.4M-5.5%	$323.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.1B+10.1%	$6.4B+7.7%	$6.0B+24.8%	$4.8B+21.2%	$4.0B+16.6%	$3.4B
Retained Earnings	$8.6B+18.5%	$7.2B+19.8%	$6.0B+19.5%	$5.0B+16.9%	$4.3B+12.4%	$3.8B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$7.9B+7.2%	$7.4B-7.0%	$7.9B+2.1%	$7.7B+5.2%	$7.4B+3.4%	$7.1B+5.9%	$6.7B+3.5%	$6.5B
Current Assets	$3.7B+6.0%	$3.5B-8.7%	$3.8B-2.9%	$3.9B+1.7%	$3.9B-3.2%	$4.0B+10.5%	$3.6B+11.4%	$3.2B
Cash & Equivalents	$1.6B+16.2%	$1.3B-15.9%	$1.6B-16.1%	$1.9B+11.9%	$1.7B+9.2%	$1.6B+14.6%	$1.4B+8.3%	$1.3B
Inventory	$183.1M+3.7%	$176.5M+4.3%	$169.2M+2.3%	$165.4M+4.7%	$157.9M+7.6%	$146.7M+7.5%	$136.5M+13.6%	$120.2M
Accounts Receivable	$350.2M+17.6%	$297.7M-21.5%	$379.3M+17.8%	$322.0M+15.3%	$279.3M-18.3%	$341.8M+17.6%	$290.7M-5.4%	$307.3M
Goodwill	$32.3M	N/A	N/A	N/A	$32.3M	N/A	N/A	N/A
Total Liabilities	$783.8M+3.0%	$760.9M+3.6%	$734.4M-21.6%	$936.7M+1.8%	$920.0M-10.0%	$1.0B-0.4%	$1.0B-11.3%	$1.2B
Current Liabilities	$560.6M+2.6%	$546.3M+3.6%	$527.1M-26.9%	$721.5M-2.2%	$738.1M-15.5%	$873.4M+4.9%	$832.3M-3.3%	$860.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.1B+7.7%	$6.6B-8.1%	$7.2B+5.4%	$6.8B+5.6%	$6.4B+5.6%	$6.1B+7.1%	$5.7B+6.7%	$5.3B
Retained Earnings	$8.6B+4.4%	$8.2B+4.3%	$7.9B+4.1%	$7.5B+4.5%	$7.2B+4.4%	$6.9B+4.7%	$6.6B+4.4%	$6.3B

UTHR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.6B+17.6%	$1.3B+35.7%	$978.0M+21.9%	$802.5M+34.2%	$598.2M-20.8%	$755.7M
Capital Expenditures	$520.5M+111.2%	$246.5M+7.0%	$230.4M+66.0%	$138.8M+14.9%	$120.8M+103.7%	$59.3M
Free Cash Flow	$1.0B-3.7%	$1.1B+44.5%	$747.6M+12.6%	$663.7M+39.0%	$477.4M-31.4%	$696.4M
Investing Cash Flow	-$551.3M-232.1%	$417.2M+158.0%	-$719.6M+11.3%	-$811.5M-66.7%	-$486.9M+34.1%	-$738.5M
Financing Cash Flow	-$1.1B+8.4%	-$1.3B-10444.5%	-$11.9M-115.8%	$75.4M+68.3%	$44.8M+365.1%	-$16.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.0B0.0%	$1.0B	$0	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$346.2M-38.4%	$562.1M+193.2%	$191.7M-58.4%	$461.2M+35.2%	$341.2M-9.5%	$377.2M+62.4%	$232.2M-38.3%	$376.5M
Capital Expenditures	$172.9M-17.9%	$210.5M+238.4%	$62.2M-17.0%	$74.9M-13.6%	$86.7M+13.3%	$76.5M+69.6%	$45.1M+18.1%	$38.2M
Free Cash Flow	$173.3M-50.7%	$351.6M+171.5%	$129.5M-66.5%	$386.3M+51.8%	$254.5M-15.4%	$300.7M+60.7%	$187.1M-44.7%	$338.3M
Investing Cash Flow	-$227.6M-261.5%	$140.9M+147.0%	-$299.9M-82.1%	-$164.7M-33.7%	-$123.2M-7.2%	-$114.9M-43.6%	-$80.0M-110.9%	$735.3M
Financing Cash Flow	$98.4M+110.3%	-$956.0M-381.4%	-$198.6M-111.7%	-$93.8M-25.6%	-$74.7M-16.5%	-$64.1M-33.5%	-$48.0M+95.5%	-$1.1B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$1.0B	$0	$0	$0	$0	$0-100.0%	$1.0B

UTHR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	87.9%-1.3pp	89.2%+0.3pp	88.9%-3.2pp	92.2%-0.6pp	92.7%+0.0pp	92.7%
Operating Margin	46.9%-1.0pp	47.9%-3.0pp	50.9%+0.3pp	50.6%+17.6pp	33.0%-7.0pp	40.0%
Net Margin	41.9%+0.4pp	41.5%-0.8pp	42.3%+4.7pp	37.6%+9.3pp	28.2%-6.5pp	34.7%
Return on Equity	18.8%+0.3pp	18.6%+2.1pp	16.5%+1.3pp	15.2%+3.1pp	12.0%-3.1pp	15.2%
Return on Assets	16.9%+0.7pp	16.2%+2.5pp	13.7%+1.7pp	12.0%+2.8pp	9.2%-2.0pp	11.2%
Current Ratio	6.60+1.4	5.25+0.8	4.41-5.4	9.85+2.2	7.61+0.9	6.70
Debt-to-Equity	0.11-0.0	0.14-0.1	0.20-0.1	0.26-0.0	0.31-0.1	0.36
FCF Margin	32.7%-4.8pp	37.5%+5.4pp	32.1%-2.2pp	34.3%+6.0pp	28.3%-18.6pp	46.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	86.9%-0.5pp	87.4%-1.6pp	89.0%+0.7pp	88.4%-1.3pp	89.7%+0.8pp	88.9%-0.2pp	89.1%-0.1pp	89.2%
Operating Margin	45.1%-3.4pp	48.6%+3.0pp	45.6%-2.6pp	48.2%-0.4pp	48.6%+2.8pp	45.8%+1.1pp	44.8%-7.8pp	52.6%
Net Margin	46.1%+3.7pp	42.4%+3.6pp	38.8%-1.8pp	40.6%-0.4pp	40.9%-0.3pp	41.3%+2.4pp	38.9%-6.3pp	45.2%
Return on Equity	5.1%-0.0pp	5.1%+0.8pp	4.3%-0.4pp	4.7%+0.1pp	4.7%-0.4pp	5.1%+0.2pp	4.9%-0.9pp	5.7%
Return on Assets	4.6%0.0pp	4.6%+0.7pp	3.9%-0.2pp	4.2%+0.1pp	4.1%-0.3pp	4.3%+0.2pp	4.1%-0.6pp	4.7%
Current Ratio	6.60+0.2	6.40-0.9	7.26+1.8	5.46+0.2	5.25+0.7	4.58+0.2	4.35+0.6	3.77
Debt-to-Equity	0.110.0	0.12+0.0	0.10-0.0	0.140.0	0.14-0.0	0.17-0.0	0.18-0.0	0.22
FCF Margin	21.9%-22.1pp	44.0%+27.8pp	16.2%-32.4pp	48.6%+14.1pp	34.6%-5.6pp	40.2%+14.0pp	26.2%-23.8pp	49.9%

Similar Companies

Teva Pharm TEVA

$35.2B

Neurocrine Biosciences Inc NBIX

$13.3B

Dr Reddys Labs RDY

$11.2B

Viatris Inc Ord Shs VTRS

$15.7B

Takeda Pharm TAK

$59.3B

Frequently Asked Questions

What is United Therapeutics Corp.'s annual revenue?

United Therapeutics Corp. (UTHR) reported $3.2B in total revenue for fiscal year 2025. This represents a 10.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is United Therapeutics Corp.'s revenue growing?

United Therapeutics Corp. (UTHR) revenue grew by 10.6% year-over-year, from $2.9B to $3.2B in fiscal year 2025.

Is United Therapeutics Corp. profitable?

Yes, United Therapeutics Corp. (UTHR) reported a net income of $1.3B in fiscal year 2025, with a net profit margin of 41.9%.

What is United Therapeutics Corp.'s EBITDA?

United Therapeutics Corp. (UTHR) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is United Therapeutics Corp.'s gross margin?

United Therapeutics Corp. (UTHR) had a gross margin of 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is United Therapeutics Corp.'s operating margin?

United Therapeutics Corp. (UTHR) had an operating margin of 46.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is United Therapeutics Corp.'s net profit margin?

United Therapeutics Corp. (UTHR) had a net profit margin of 41.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is United Therapeutics Corp.'s return on equity (ROE)?

United Therapeutics Corp. (UTHR) has a return on equity of 18.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is United Therapeutics Corp.'s free cash flow?

United Therapeutics Corp. (UTHR) generated $1.0B in free cash flow during fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is United Therapeutics Corp.'s operating cash flow?

United Therapeutics Corp. (UTHR) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are United Therapeutics Corp.'s total assets?

United Therapeutics Corp. (UTHR) had $7.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are United Therapeutics Corp.'s capital expenditures?

United Therapeutics Corp. (UTHR) invested $520.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does United Therapeutics Corp. spend on research and development?

United Therapeutics Corp. (UTHR) invested $550.0M in research and development during fiscal year 2025.

Does United Therapeutics Corp. buy back shares?

Yes, United Therapeutics Corp. (UTHR) spent $1.0B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does United Therapeutics Corp. have outstanding?

United Therapeutics Corp. (UTHR) had 44M shares outstanding as of fiscal year 2025.

What is United Therapeutics Corp.'s current ratio?

United Therapeutics Corp. (UTHR) had a current ratio of 6.60 as of fiscal year 2025, which is generally considered healthy.

What is United Therapeutics Corp.'s debt-to-equity ratio?

United Therapeutics Corp. (UTHR) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is United Therapeutics Corp.'s return on assets (ROA)?

United Therapeutics Corp. (UTHR) had a return on assets of 16.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is United Therapeutics Corp.'s Altman Z-Score?

United Therapeutics Corp. (UTHR) has an Altman Z-Score of 22.16, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is United Therapeutics Corp.'s Piotroski F-Score?

United Therapeutics Corp. (UTHR) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are United Therapeutics Corp.'s earnings high quality?

United Therapeutics Corp. (UTHR) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can United Therapeutics Corp. cover its interest payments?

United Therapeutics Corp. (UTHR) has an interest coverage ratio of 76.5x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is United Therapeutics Corp.?

United Therapeutics Corp. (UTHR) scores 84 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.